Dengue is an Aedes mosquito-transmitted acute disease. Caused by infection with 4 different dengue viruses (DENV-1 to -4), with further genetic diversity within each of the four DENVs, pathogenesis of and immunity to this disease are complex and are currently understood only in patches. These knowledge gaps hamper our ability to prevent dengue effectively, resulting in more people around the world living at risk of potentially life-threatening illness.
The DENgue Virology and Immunology (DENVI) Group brings together 3 labs, 1 computational biology and 2 clinical trial teams from Duke-NUS Medical School and Singapore General Hospital. We bring complementary expertise, from molecular virology and immunology to systems biology and clinical trials to study and understand dengue pathogenesis and immunity in humans.
We hope to contribute evidence-based insights to support vaccine development and deployment as well as accelerate clinical translation of new anti-dengue therapies.
Take a look at the impactful research and scientific discoveries we’ve contributed to.